NL8601285A - Farmaceutische preparaten voor nasale toediening. - Google Patents

Farmaceutische preparaten voor nasale toediening. Download PDF

Info

Publication number: NL8601285A
Authority: NL; Netherlands
Prior art keywords: insert according; insert; calcitonin; nose; active agent
Prior art date: 1985-06-04

Application number

NL8601285A

Other languages

English (en)

Dutch (nl)

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-06-04

Filing date

1986-05-21

Publication date

1987-01-02

1986-05-21 Application filed by Sandoz Ag filed Critical Sandoz Ag

1987-01-02 Publication of NL8601285A publication Critical patent/NL8601285A/nl

Links

239000000825 pharmaceutical preparation Substances 0.000 title description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical group N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 34
210000001331 nose Anatomy 0.000 claims description 24
239000013543 active substance Substances 0.000 claims description 22
-1 hydroxypropylmethyl Chemical group 0.000 claims description 21
108090000765 processed proteins & peptides Proteins 0.000 claims description 20
108060001064 Calcitonin Proteins 0.000 claims description 19
102000055006 Calcitonin Human genes 0.000 claims description 18
229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 18
108010068072 salmon calcitonin Proteins 0.000 claims description 18
108010010803 Gelatin Proteins 0.000 claims description 17
239000008273 gelatin Substances 0.000 claims description 17
229920000159 gelatin Polymers 0.000 claims description 17
235000019322 gelatine Nutrition 0.000 claims description 17
235000011852 gelatine desserts Nutrition 0.000 claims description 17
239000000463 material Substances 0.000 claims description 17
229960004015 calcitonin Drugs 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 13
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
239000011159 matrix material Substances 0.000 claims description 11
238000000034 method Methods 0.000 claims description 11
210000002850 nasal mucosa Anatomy 0.000 claims description 10
239000007787 solid Substances 0.000 claims description 9
239000007788 liquid Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 5
238000003780 insertion Methods 0.000 claims description 5
230000037431 insertion Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 3
230000000717 retained effect Effects 0.000 claims description 3
238000001704 evaporation Methods 0.000 claims description 2
238000002791 soaking Methods 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
239000000047 product Substances 0.000 description 45
229920003171 Poly (ethylene oxide) Polymers 0.000 description 19
239000011148 porous material Substances 0.000 description 17
239000000243 solution Substances 0.000 description 17
MINDHVHHQZYEEK-HBBNESRFSA-N mupirocin Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 description 16
150000002170 ethers Chemical class 0.000 description 14
238000010521 absorption reaction Methods 0.000 description 8
239000000203 mixture Substances 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
238000004108 freeze drying Methods 0.000 description 6
239000007922 nasal spray Substances 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
239000011575 calcium Substances 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
229940097496 nasal spray Drugs 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000012384 transportation and delivery Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000011149 active material Substances 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
229920001451 polypropylene glycol Polymers 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
229920003169 water-soluble polymer Polymers 0.000 description 3
QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical group C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 2
ZFGOPJASRDDARH-UHFFFAOYSA-N 3-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C(C2)C1(C)CCC2OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 ZFGOPJASRDDARH-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
108010019393 Fibrin Foam Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Chemical group C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
229940099367 lanolin alcohols Drugs 0.000 description 2
CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical group C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 2
229940058690 lanosterol Drugs 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
229910052753 mercury Inorganic materials 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229940051841 polyoxyethylene ether Drugs 0.000 description 2
229920000056 polyoxyethylene ether Polymers 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
150000003871 sulfonates Chemical class 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000002268 wool Anatomy 0.000 description 2
BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
MBZYKEVPFYHDOH-UHFFFAOYSA-N (10S)-3c-Hydroxy-4.4.10r.13t.14c-pentamethyl-17t-((R)-1.5-dimethyl-hexyl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(C)CCCC(C)C)CCC21C MBZYKEVPFYHDOH-UHFFFAOYSA-N 0.000 description 1
CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical class CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical class CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
RKZIPFOHRUCGGS-UHFFFAOYSA-N 4,5-dihydroimidazole-1-carboxylic acid Chemical class OC(=O)N1CCN=C1 RKZIPFOHRUCGGS-UHFFFAOYSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
241000277263 Salmo Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000002280 amphoteric surfactant Substances 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical class C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 1
108700032313 elcatonin Proteins 0.000 description 1
229960000756 elcatonin Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000002657 fibrous material Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229940045644 human calcitonin Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
YWFWDNVOPHGWMX-UHFFFAOYSA-N n,n-dimethyldodecan-1-amine Chemical compound CCCCCCCCCCCCN(C)C YWFWDNVOPHGWMX-UHFFFAOYSA-N 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
238000003672 processing method Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000000344 soap Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
125000002328 sterol group Chemical group 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000004711 α-olefin Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Immunology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Otolaryngology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8601285A 1985-06-04 1986-05-21 Farmaceutische preparaten voor nasale toediening. NL8601285A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8514090		1983-06-04
GB858514090A GB8514090D0 (en)	1985-06-04	1985-06-04	Organic compounds

Publications (1)

Publication Number	Publication Date
NL8601285A true NL8601285A (nl)	1987-01-02

Family

ID=10580163

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8601285A NL8601285A (nl)	1985-06-04	1986-05-21	Farmaceutische preparaten voor nasale toediening.

Country Status (21)

Country	Link
US (1)	US4988512A (fr)
JP (1)	JPS61282320A (fr)
KR (1)	KR870000066A (fr)
AU (1)	AU5824786A (fr)
BE (1)	BE904863A (fr)
CH (1)	CH668913A5 (fr)
DE (1)	DE3617728A1 (fr)
DK (1)	DK259186A (fr)
ES (1)	ES8801130A1 (fr)
FR (1)	FR2582511B1 (fr)
GB (3)	GB8514090D0 (fr)
GR (1)	GR861422B (fr)
HU (1)	HU199300B (fr)
IL (1)	IL78980A0 (fr)
IT (1)	IT1214683B (fr)
LU (1)	LU86457A1 (fr)
NL (1)	NL8601285A (fr)
NZ (1)	NZ216393A (fr)
PT (1)	PT82691B (fr)
SE (1)	SE8602530L (fr)
ZA (1)	ZA864164B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH657779A5 (de) *	1982-10-05	1986-09-30	Sandoz Ag	Galenische zusammensetzungen enthaltend calcitonin.
DE3726517A1 (de) *	1986-08-18	1988-03-03	Sandoz Ag	Nasale zusammensetzungen, welche octreotid enthalten
MY102411A (en) *	1986-12-23	1992-06-17	Ciba Geigy Ag	Nasal solutions
GB8712176D0 (en) *	1987-05-22	1987-06-24	Cosmas Damian Ltd	Drug delivery system
US5690954A (en) *	1987-05-22	1997-11-25	Danbiosyst Uk Limited	Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8723846D0 (en) *	1987-10-10	1987-11-11	Danbiosyst Ltd	Bioadhesive microsphere drug delivery system
US5026825A (en) *	1988-09-08	1991-06-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Intranasal calcitonin formulations
GB9020544D0 (en) *	1990-09-20	1990-10-31	Sandoz Ltd	Improvements in or relating to organic compounds
HU222249B1 (hu) *	1991-03-08	2003-05-28	Amylin Pharmaceuticals Inc.	Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DE4115849A1 (de) *	1991-05-15	1992-11-19	Lohmann Therapie Syst Lts	Penetrationsfoerdernde substanz
ES2108122T3 (es) *	1991-05-24	1997-12-16	Amylin Pharmaceuticals Inc	Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
DE4140192C2 (de) *	1991-12-05	1996-02-29	Alfatec Pharma Gmbh	Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
WO1993013753A1 (fr) *	1992-01-17	1993-07-22	Alfatec-Pharma Gmbh	Comprimes contenant des medicaments peptidiques, leur fabrication et leur application
HUT75616A (en) *	1992-03-17	1997-05-28	Pfizer	Method for prooucing porous delivery devices
GB9623205D0 (en) *	1996-11-07	1997-01-08	Eurand Int	Novel pharmaceutical compositions
EP1061987B1 (fr) *	1998-02-13	2006-05-17	Bioniche Life Sciences Inc.	Dispositif servant a administrer un medicament
TWI243687B (en) *	1998-04-21	2005-11-21	Teijin Ltd	Pharmaceutical composition for application to mucosa
US6759393B1 (en)	1999-04-12	2004-07-06	Pfizer Inc.	Growth hormone and growth hormone releasing hormone compositions
US7812120B2 (en)	2003-03-21	2010-10-12	Par Pharmaceutical, Inc.	Nasal calcitonin formulations containing chlorobutanol
WO2005097210A1 (fr) *	2004-03-26	2005-10-20	The University Of Utah Research Foundation	Systeme polymere biosensible pour l'administration de microbicides
US7396936B1 (en)	2004-11-09	2008-07-08	Kemia, Inc.	Modulators of calcitonin and amylin receptor activity

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US820948A (en) *	1905-01-23	1906-05-22	Edward Baum	Device fot treating the nasal passages.
US3234091A (en) *	1955-07-08	1966-02-08	Ciba Geigy Corp	Shaped medicaments and process for their manufacture
DE1617564A1 (de) *	1966-12-03	1971-04-01	Rudolf Kisro	Arzneimitteltraeger
DK135268A (fr) *	1973-02-09
GB1548022A (en) *	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
US4164560A (en) *	1977-01-05	1979-08-14	Folkman Moses J	Systems for the controlled release of macromolecules
US4391797A (en) *	1977-01-05	1983-07-05	The Children's Hospital Medical Center	Systems for the controlled release of macromolecules
GB2042888B (en) *	1979-03-05	1983-09-28	Teijin Ltd	Preparation for administration to the mucosa of the oral or nasal cavity
JPS6034925B2 (ja) *	1979-07-31	1985-08-12	帝人株式会社	持続性鼻腔用製剤およびその製造法
JPS56100714A (en) *	1980-01-16	1981-08-12	Teijin Ltd	Pharmaceutical adhering to oral mucous membrane or nasal mucous membrane
JPS576403A (en) *	1980-06-12	1982-01-13	Toshiba Corp	Recording and reproducing device
GB2090535B (en) *	1981-01-06	1984-09-19	Osman Mohammad Fekry	Medical inserts
JPS5921613A (ja) *	1982-07-28	1984-02-03	Takeda Chem Ind Ltd	直腸投与製剤
GB2127689B (en) *	1982-10-05	1986-07-09	Sandoz Ltd	Calcitonin inhalation compositions
US4452775A (en) *	1982-12-03	1984-06-05	Syntex (U.S.A.) Inc.	Cholesterol matrix delivery system for sustained release of macromolecules
FR2537980B1 (fr) *	1982-12-17	1986-12-19	Sandoz Sa	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
IL70489A0 (en) *	1982-12-29	1984-03-30	Armour Pharma	Pharmaceutical compositions containing calcitonin
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
US4591496A (en) *	1984-01-16	1986-05-27	Massachusetts Institute Of Technology	Process for making systems for the controlled release of macromolecules

1985
- 1985-06-04 GB GB858514090A patent/GB8514090D0/en active Pending
1986
- 1986-05-21 NL NL8601285A patent/NL8601285A/nl not_active Application Discontinuation
- 1986-05-21 HU HU862159A patent/HU199300B/hu unknown
- 1986-05-27 CH CH2137/86A patent/CH668913A5/de not_active IP Right Cessation
- 1986-05-27 DE DE19863617728 patent/DE3617728A1/de not_active Ceased
- 1986-06-02 PT PT82691A patent/PT82691B/pt unknown
- 1986-06-02 GB GB8613284A patent/GB2176105B/en not_active Expired - Lifetime
- 1986-06-02 AU AU58247/86A patent/AU5824786A/en not_active Abandoned
- 1986-06-02 GR GR861422A patent/GR861422B/el unknown
- 1986-06-02 DK DK259186A patent/DK259186A/da not_active Application Discontinuation
- 1986-06-02 IL IL78980A patent/IL78980A0/xx unknown
- 1986-06-02 KR KR1019860004329A patent/KR870000066A/ko not_active Ceased
- 1986-06-03 FR FR868607979A patent/FR2582511B1/fr not_active Expired
- 1986-06-03 NZ NZ216393A patent/NZ216393A/xx unknown
- 1986-06-03 BE BE1/011501A patent/BE904863A/fr not_active IP Right Cessation
- 1986-06-03 JP JP61130010A patent/JPS61282320A/ja active Pending
- 1986-06-03 ES ES555676A patent/ES8801130A1/es not_active Expired
- 1986-06-04 ZA ZA864164A patent/ZA864164B/xx unknown
- 1986-06-04 SE SE8602530A patent/SE8602530L/xx not_active Application Discontinuation
- 1986-06-04 LU LU86457A patent/LU86457A1/fr unknown
- 1986-06-04 IT IT8648098A patent/IT1214683B/it active
1989
- 1989-03-22 GB GB8906584A patent/GB2213377A/en not_active Withdrawn
- 1989-09-18 US US07/408,641 patent/US4988512A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HU199300B (en)	1990-02-28
GB2176105A (en)	1986-12-17
DK259186A (da)	1986-12-05
GB2213377A (en)	1989-08-16
IT8648098A0 (it)	1986-06-04
FR2582511A1 (fr)	1986-12-05
IL78980A0 (en)	1986-09-30
GB2176105B (en)	1990-03-07
FR2582511B1 (fr)	1989-05-26
PT82691B (en)	1988-05-03
IT1214683B (it)	1990-01-18
PT82691A (en)	1986-07-01
ES555676A0 (es)	1988-01-01
GR861422B (en)	1986-10-01
GB8906584D0 (en)	1989-05-04
LU86457A1 (fr)	1987-01-13
GB8514090D0 (en)	1985-07-10
KR870000066A (ko)	1987-02-16
SE8602530D0 (sv)	1986-06-04
BE904863A (fr)	1986-12-03
ZA864164B (en)	1988-01-27
GB8613284D0 (en)	1986-07-09
HUT49288A (en)	1989-09-28
SE8602530L (sv)	1986-12-05
NZ216393A (en)	1989-08-29
CH668913A5 (de)	1989-02-15
AU5824786A (en)	1986-12-11
JPS61282320A (ja)	1986-12-12
US4988512A (en)	1991-01-29
ES8801130A1 (es)	1988-01-01
DK259186D0 (da)	1986-06-02
DE3617728A1 (de)	1986-12-04

Legal Events

Date	Code	Title	Description
1991-01-02	BV	The patent application has lapsed

Publication	Publication Date	Title
US4988512A (en)	1991-01-29	Nasal pharmaceutical compositions
US5514673A (en)	1996-05-07	Pharmaceutical composition containing lipophilic drugs
US5346701A (en)	1994-09-13	Transmucosal delivery of macromolecular drugs
RU2493868C2 (ru)	2013-09-27	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
AU2016220235B2 (en)	2021-04-29	Nasal powder formulation for treatment of hypoglycemia
US20020197324A1 (en)	2002-12-26	Delivery of drugs to mucosal surfaces
GB2248550A (en)	1992-04-15	Nasal pharmaceutical composition
CN101151048A (zh)	2008-03-26	增强甲状旁腺激素粘膜递送的组合物和方法
JPH08505364A (ja)	1996-06-11	カルシトニン含有医薬組成物
CY1704A (en)	1994-01-14	Nasal pharmaceutical composition containing a somatostatin anologue
Quadir et al.	2000	Development and evaluation of nasal formulations of ketorolac
JPH11505222A (ja)	1999-05-18	２〜６時間の活性成分放出期間をもつ上皮小体ホルモンの医薬投与形態
KR20140041686A (ko)	2014-04-04	겔 조성물
AT396331B (de)	1993-08-25	Verfahren zur herstellung einer octreotid enthaltenden pharmazeutischen zusammensetzung
BR112020024399A2 (pt)	2021-03-02	composição líquida sem água e sistema para administração transmucosal oral de um ingrediente ativo através de uma composição líquida
US6350472B1 (en)	2002-02-26	Method of treating HIV infection with transdermal gel containing mammalian liver extract
JPS6357528A (ja)	1988-03-12	新規製剤
Dondeti	1994	Optimization of nasal delivery of insulin
HK1208626A1 (en)	2016-03-11	Long-acting controlled-release liposome gel composition comprising hypoglycemic active ingredient and preparation method thereof
HK1208626B (en)	2019-11-08	Long-acting controlled-release liposome gel composition comprising hypoglycemic active ingredient and preparation method thereof
JPH0725662B2 (ja)	1995-03-22	使用時調製型上皮細胞成長因子含有水性薬剤の安定化方法
CN117731788A (zh)	2024-03-22	一种可克服生物屏障的肺部递送药物组合物、制备方法及其应用